By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Poxel SAS 

200 avenue Jean Jaures

Lyon    69007  France
Phone: 33-4-37-372010 Fax: 33-4-37-708815



Company News
Poxel SAS Presents New Data On Imeglimin And PXL770 At The European Association For The Study Of Diabetes Annual Meeting 9/15/2016 11:37:20 AM
Poxel SAS To Present At The 18th Annual Rodman & Renshaw Global Investment Conference September 11-13th, 2016 9/6/2016 12:48:53 PM
Poxel SAS To Present New Imeglimin And PXL770 Data At The 52nd European Association For The Study Of Diabetes Annual Meeting 9/6/2016 11:44:30 AM
Poxel SAS Closes a €26.5 Million Capital Increase 7/18/2016 10:33:27 AM
Poxel SAS Announces Patient Enrollment Completed For Imeglimin Phase 2b Clinical Trial In Type 2 Diabetes In Japan 6/30/2016 9:10:39 AM
Poxel SAS Announces Positive Results From the First Stage Of The Ongoing PXL770 Phase 1 Trial 6/20/2016 11:56:13 AM
Poxel Presents New Data On Imeglimin’s Dual Mechanism Of Action At The American Diabetes Association’s 76th Scientific Sessions 6/13/2016 10:49:13 AM
Poxel Has Been Granted U.S. Composition Of Matter Patent For Direct AMPK Activator PXL770 For The Potential Treatment Of Type 2 Diabetes And Related Disorders 3/29/2016 11:12:31 AM
Poxel SAS Appoints Jonae R. Barnes As Senior Vice President Investor Relations And Public Relations, Based In Boston 3/14/2016 9:06:57 AM
Poxel SAS Appoints Janice Bourque And Pierre Legault To Its Board Of Directors 2/1/2016 10:25:41 AM